다발성 골수종

40개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved40 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleShanghai Changzheng HospitalPhase 1

CAR-T cells Infusion (CAR-T cells Infusion)

Relapsed/Refractory Multiple Myeloma; Relapsed/Refractory Plasma Cell Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 2

CAR-T treatment (CAR-T treatment)

Multiple Myeloma; Relapsed/Refractory · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 1

CAR19BCMA-T cells (CAR19BCMA-T cells)

Relapsed or Refractory Plasma Cell Neoplasms; Lymphomas/Leukemias With Plasmacytic Differentiation · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSorrento Therapeutics, Inc.Phase 1

CAR2 Anti-CD38 A2 CAR-T Cells (CAR2 Anti-CD38 A2 CAR-T Cells)

Relapsed or Refractory Multiple Myeloma · CD38

#CD38#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleYihao WangPhase 2

CD19/BCMA CAR-T (CD19/BCMA CAR-T)

Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

CD19/CD20/BCMA CAR-T (CD19/CD20/BCMA CAR-T)

Relapsed; Refractory · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

Daratumumab (CT-P44, CT-P44(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryorRelapsedMultipleMyel+1
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Preclinical

CT0590 CAR T Cells (CT0590 CAR T Cells)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleO&D BioTech Group CO., LimitedPhase 1

Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D (Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D)

Relapsed or Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryorRelapsedMultipleMyel+1
Trials 1Status Recruiting
CGTLimited DatastaleCartesian TherapeuticsPhase 1

Descartes-15 (Descartes-15)

Refractory Multiple Myeloma; Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHadassah Medical OrganizationPhase 1

Naive HBI0101 CAR-T (Naive HBI0101 CAR-T)

Relapsed/Refractory Multiple Myeloma (MM) · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedRefractoryMultipleMyelom+1
Trials 1Status Recruiting
CGTLimited DatastaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleRui Therapeutics Co., LtdPhase 1

anti-CD19/BCMA U CAR T (anti-CD19/BCMA U CAR T)

Relapsed/Refractory Immune Nephropathy; Relapsed/Refractory Immune-mediated Kidney Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →